ALX Oncology's 8-Year CD47 Fork: 7 Data Commits, Still Waiting on Cancer's Merge Review

On January 15, 2026, ALX Oncology Holdings Inc. (ALXO) presented at the 44th Annual J.P. Morgan Healthcare Conference, which was attended by industry professionals and hosted by JPMorgan's Henry Jiang. The presentation, led by Jason Lettmann, CEO & Director, and Barbara Klencke, Interim Chief Medical Officer, highlighted the company's progress in developing its clinical stage programs, evorpacept and ALX2004, both of which have shown strong potential in the oncology field. As a company founded in 2015 with a focus on the CD47 target, ALX Oncology has made significant strides in understanding the importance of this target in the immune system and its application in oncology, with 7 different data sets read out in the previous year. Lettmann noted that the company has had an "incredible year" with substantial progress in both programs, which are highly differentiated in their class, and expressed excitement about the company's future prospects. With the presentation marking a significant milestone for the company, ALX Oncology aims to continue advancing its programs and exploring the potential of its targeted therapies in the treatment of cancer.